US Patent 8,883,842 scope, claims, and U.S. patent landscape for bortezomib combination therapy in resistant multiple myeloma
Executive summary: US Patent 8,883,842 claims a specific therapeutic method for multiple myeloma that is resistant to conventional therapy (and dependent claim resistance to bortezomib) using a synergistically effective combination of (i) N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide (a compound defined by formula (III)) and (ii) bortezomib. The claims are method-of-treatment claims with combination administration and a resistance/line-of-therapy phenotype as the eligibility limitation. For U.S. freedom-to-operate (FTO) work, the estate’s practical scope is concentrated in: (1) the pairing with bortezomib, (2) the specific formula (III) compound, (3) the synergy requirement, and (4) resistant multiple myeloma patient selection.
What is US Patent 8,883,842 and what does it claim about multiple myeloma resistance?
Claim set (as provided):
Claim 1. A method of treating multiple myeloma in a human patient “in need thereof,” comprising administering in an amount “which is synergistically effective” a combination of:
- N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide having formula (III) or a pharmaceutically acceptable salt; and
- bortezomib or a pharmaceutically acceptable salt,
where the multiple myeloma is resistant to conventional therapy.
Claim 2. The method of claim 1, where the multiple myeloma is resistant to bortezomib.
Practical claim construction points for U.S. litigation or FTO
- “Method of treating”: infringement is tied to clinical administration in a qualifying patient population, not a product manufacture claim.
- “Combination”: requires both agents to be administered as part of the same treatment regimen; the claim as written does not specify whether concurrent or sequential dosing is required, but “combination” in method-of-treatment claims is typically argued as a co-therapeutic regimen rather than complete independence.
- “Synergistically effective”: injects a functional requirement. In practice this can become a key issue: whether the accused regimen produces synergy relative to what would be expected from each component alone.
- “Resistant to conventional therapy” (claim 1) and “resistant to bortezomib” (claim 2) add a disease-state limitation that can narrow the covered population and affect both infringement and inducement arguments.
What the resistance limitations likely do to the claim’s reach
- Claim 1 is not limited to bortezomib-refractory disease; it covers conventional-therapy resistant multiple myeloma broadly. Claim 2 tightens further to bortezomib-resistant disease.
- From an FTO perspective, the resistance phenotype can be litigated via: prior treatment history, response criteria, and timing.
How broad is the scope of formula (III) in US 8,883,842? Is it limited to one compound or a class?
As drafted, claim 1 is limited to a single identified chemical entity (N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide) and its pharmaceutically acceptable salts. The claim does not appear to target a broader chemical class using Markush language (based on the provided text).
Scope implications
- Substitutions, prodrugs, or alternative stereoisomers are not clearly included unless they fall within the literal wording “having the formula (III)” as interpreted by the patent’s definition.
- The phrase “having the formula (III)” usually ties coverage to a specific structure definition in the specification. If the patent defines formula (III) precisely, the claim likely reads on salts and potentially tautomers/isomeric forms that remain within the defined structural formula.
Key enforceability leverage
- Chemical specificity is beneficial for both claim clarity and invalidity defense. If an accused regimen uses a different indole-derived N-hydroxy propenamide scaffold that is not the same formula (III), infringement arguments weaken unless doctrine of equivalents is pursued.
What does “synergistically effective” mean in US 8,883,842, and how could it be proven in court?
Claim language:
- “administering in an amount which is synergistically effective”
Litigation-critical consequences
- Synergy is not just a marketing descriptor. It is a claim limitation. In the U.S., that means the patent owner generally must show that the combination regimen meets the functional “synergy” standard.
- The burden often turns on whether the patent specification provides definitional guidance:
- threshold statistical measures,
- comparative design (combination vs. monotherapy),
- assays (in vitro, in vivo),
- clinical endpoints.
Proof routes commonly used for synergy limitations
- Preclinical combination studies showing supra-additive inhibition or tumor regression.
- Translating preclinical synergy to patient treatment may be argued, depending on how the specification links synergy to clinical efficacy in resistant multiple myeloma.
Which bortezomib regimens are covered by US 8,883,842? Does it require bortezomib monotherapy as the second agent?
Claim 1 requires administration of bortezomib (or pharmaceutically acceptable salt) as part of the combination.
What is covered based on claim text
- A regimen where the patient receives:
- the formula (III) compound (or salt), and
- bortezomib (or salt),
- in a synergistically effective amount.
What is not explicitly required
- The provided claim text does not restrict route (IV vs SC), dosing schedule, line of therapy beyond “resistant to conventional therapy,” or co-administration with third agents.
- In practice, if the accused regimen includes bortezomib plus the formula (III) compound, the patent owner can argue that the claim is met even if other therapies are included, depending on how the “combination” is interpreted and whether other agents affect the synergy requirement.
What is the likely claim coverage for bortezomib-refractory multiple myeloma vs conventional-therapy-resistant disease?
Claim 1 (broad phenotype): multiple myeloma resistant to conventional therapy.
Claim 2 (narrow phenotype): multiple myeloma resistant to bortezomib.
Infringement mapping (conceptual)
- If an accused regimen targets patients who have had inadequate response to bortezomib, claim 2 becomes a focal point.
- If patients are bortezomib-experienced but only “conventional-therapy resistant” is documented (not explicitly “bortezomib-resistant”), claim 1 still has potential traction.
Regulatory and clinical documentation impact
- Disease resistance status is typically supported by:
- prior exposure,
- progression dates,
- response definitions in trial protocols.
- For method claims, these records can drive evidence strength.
How many other U.S. patents typically surround bortezomib combination therapy in resistant multiple myeloma?
A U.S. bortezomib-centered combination landscape in multiple myeloma is usually crowded due to:
- broad bortezomib formulation and dosing patents,
- combination regimen patents (often by partner drug and disease context),
- method-of-treatment patents tied to patient subpopulations (refractory disease, prior-line status),
- use of bortezomib analogs/salts.
For US 8,883,842 specifically, the claim text you provided indicates a partner-drug-specific combination method. That positioning generally means the strongest adjacent risks are:
- patents describing the same formula (III) compound (or close analogs) in combination with known myeloma agents,
- patents describing bortezomib combinations in resistant/refractory settings that could overlap via synergy or patient selection,
- patents about salts, polymorphs, or dosing for the formula (III) compound if those details are pleaded via separate claims.
Because you provided only the two claims and not the patent bibliographic data, no defensible count of “how many patents cover” can be produced without risking inaccuracy.
What would an Orange Book and FDA status review likely show for this patent type?
Claim type: method-of-treatment.
Typical Orange Book presence: Method claims generally do not appear as Orange Book listings (Orange Book focuses on approved drug products and approved active ingredients, plus patent claims that are listed to cover product and method-of-use as submitted under 21 U.S.C. § 355(b)(1) and (c)(2)). Some method-of-use patents can be listed if they meet listing requirements and are tied to the drug.
Without the drug application number, listing numbers, or the active ingredient name for the formula (III) compound’s approved status, no accurate Orange Book listing mapping can be provided from the information in the prompt alone.
When does US 8,883,842 lose exclusivity in the U.S.?
A patent’s loss of exclusivity in the U.S. is driven by:
- statutory patent term (filing date-based),
- potential PTA (patent term adjustment),
- terminal disclaimers,
- expiration and any active litigation/appeal effects.
No filing date, priority date, PTA amount, or terminal disclaimer terms are included in your prompt. Without those inputs, any expiration date would be speculative.
How strong is the patent estate of US 8,883,842 based on claim mechanics?
Based strictly on the two claims provided:
Strength drivers
- Specific chemical entity (formula (III) compound) + known drug (bortezomib) is a clear combination nexus.
- Resistance limitation can limit prior art and sharpen clinical relevance.
- Dependent claim 2 adds a tighter subset: bortezomib-resistant disease.
Vulnerabilities to anticipate in U.S. challenges
- Synergy limitation can be attacked as:
- insufficiently supported,
- indefinite, or
- not proven to meet claimed thresholds.
- Prior art could exist for:
- combining a bortezomib regimen with other propenamides/indole derivatives in myeloma,
- refractory disease contexts,
- synergy claims made via generic “combination improves outcomes” language.
- If prior art discloses the partner compound + bortezomib in refractory multiple myeloma, novelty/obviousness exposure increases.
What patent infringement theories apply to method claims like these? Direct infringement vs inducement vs contributory infringement
For a method-of-treatment claim:
- Direct infringement typically requires a physician or the healthcare provider to administer the claimed combination to a patient meeting the resistance phenotype.
- Inducement can be argued against sponsor/manufacturer entities that encourage use.
- Contributory infringement generally depends on whether the entity provides a component with knowledge that it is especially made for the patented method.
The resistance limitation matters because it can require proving the patient population was actually “resistant” under the patent’s construed standard.
What generic entry risks exist if a formula (III) compound approaches commercialization with bortezomib?
If the formula (III) compound is not itself a generic but a new chemical entity or specialty active, generic entry risk can manifest as:
- biosimilar-type analogs are unlikely because it is a small molecule partner to bortezomib.
- generic substitution risk depends on whether the formula (III) compound is subject to ANDA-type replication, and whether any patent listings for method-of-use exist and trigger Paragraph IV strategies.
If a company launches a regimen combining:
- the formula (III) compound (or covered salt/form) and
- bortezomib,
in the intended resistant patient population, it creates direct infringement risk if the combination is “synergistically effective” within the patent’s evidentiary framing.
Key Takeaways
- US 8,883,842 is a narrow method-of-treatment combination patent: it ties infringement to administering a synergistically effective combination of a specific formula (III) N-hydroxy propenamide and bortezomib to patients with conventional-therapy resistant multiple myeloma.
- Claim 2 further narrows to bortezomib-resistant disease, creating a smaller but higher-evidence patient subset for enforcement.
- The two central litigation levers are:
- whether the administered partner drug is literally within formula (III) (including salt status), and
- whether the accused regimen satisfies the “synergistically effective” functional limitation.
- Without bibliographic and regulatory identifiers, this analysis cannot produce defensible specifics on:
- expiration dates,
- Orange Book patent listings,
- number of adjacent U.S. patents,
- Paragraph IV or litigation outcomes.
FAQs
1) Does US 8,883,842 cover adding bortezomib to the formula (III) compound as well as adding the formula (III) compound to bortezomib?
Yes. The claim requires administration of both agents in a synergistically effective combination; directionality is not reversed by wording.
2) If a patient receives the combination plus a third myeloma agent, is the regimen still potentially covered?
The claim text requires the two specified agents and synergy; coverage can still be argued if the regimen includes both and meets the synergy limitation, depending on claim construction of “combination.”
3) What patient record evidence most affects infringement for claim 1 vs claim 2?
Records showing that the patient’s multiple myeloma is resistant to conventional therapy for claim 1, and specifically resistant to bortezomib for claim 2.
4) Can design-around be done by switching to a different N-hydroxy propenamide scaffold?
Potentially. The claim is tied to the specific chemical identified by formula (III); a different scaffold can fall outside literal scope.
5) What is the most common vulnerability for synergy-based combination method claims in U.S. validity challenges?
Whether the synergy requirement is adequately supported in the specification and whether prior art combinations render the claimed functional outcome obvious or not credibly different.
References (APA)
- US Patent 8,883,842. (Claims 1-2 as provided in prompt).
